SCHEMBL15435537

SCHEMBL15435537

Nc1cccn(CC=O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.38
PARP1 P09874 1/20 0.36
EGLN1 Q9GZT9 2/20 0.34
VEGFA P15692 1/20 0.34
NPC1 O15118 7/20 0.33
KMT2A Q03164 4/20 0.33
RAB9A P51151 6/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
BRD4 O60885 1/20 0.30
BRD2 P25440 1/20 0.30
BRD3 Q15059 1/20 0.30
BRDT Q58F21 1/20 0.30
POLB P06746 1/20 0.30
CYP3A4 P08684 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15333307 0.77 PKM (0.45) EGLN1VEGFANPC1KMT2ARAB9A
SCHEMBL20386728 0.77 EGLN1 (0.53) EGLN1VEGFANPC1KMT2ARAB9A
SCHEMBL25433288 0.76 ELANE (0.43) ELANEPARP1EGLN1VEGFARAB9A
SCHEMBL13923526 0.76 ELANE (0.46) ELANEPARP1EGLN1VEGFAKMT2A
SCHEMBL15803813 0.76 ELANE (0.37) ELANEPARP1EGLN1VEGFAKMT2A
SCHEMBL20697298 0.73 PARP1 (0.46) ELANEPARP1EGLN1VEGFANPC1
SCHEMBL15804049 0.73 BRD4 (0.54) EGLN1VEGFANPC1RAB9AALDH1A1
SCHEMBL15804040 0.72 ELANE (0.46) ELANEPARP1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL197253 0.72 ELANE (0.49) ELANEPARP1KMT2ARAB9AMEN1
SCHEMBL7021949 0.72 ELANE (0.49) ELANEPARP1EGLN1VEGFAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
EP-2687511-A1 Pyridinone derivatives as tissue transglutaminase inhibitors Zedira GmbH (DE) 2014-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 ELANE 1392/4885PARP1 2569/4885EGLN1 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.